Naldemedine

Description: Naldemedine (S 297995) is a peripheral selective µ-opioid receptor antagonist being developed by Shionogi for the treatment of opioid-induced adverse reactions, including constipation, nausea, and vomiting. They are usually well tolerated, mainly with mild to moderate gastrointestinal side effects. Target: Others. Smiles: O[C@]12[C@@]34C=5C(O[C@]3(C(O)=C(C(NC(C)(C)C6=NC(=NO6)C7=CC=CC=C7)=O)C1)[H])=C(O)C=CC5C[C@]2(N(CC8CC8)CC4)[H]. References: Webster L, Nagata T, Yamada T, Arjona Ferreira J. (479) A phase 2a, randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety and efficacy of naldemedine in patients with chronic non-cancer pain and opioid-induced bowel dysfunction. J Pain. 2016 Apr,17(4S):S94. doi: 10.1016/j.jpain.2016.01.456. PubMed PMID: 28162732.